{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T18:25:48Z","timestamp":1783103148455,"version":"3.54.6"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ajo.2025.11.036","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T07:49:05Z","timestamp":1764834545000},"page":"163-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Efficacy and Safety of SJP-0132 in Patients With Dry Eye Disease: A Phase 2b Randomized, Double-Masked, Dose-Finding Study"],"prefix":"10.1016","volume":"283","author":[{"given":"Yuichi","family":"Hori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8753-1506","authenticated-orcid":false,"given":"Tomoyuki","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Omatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Arita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Dannoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shima","family":"Fukuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Setsuko","family":"Hashida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiko","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Inazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Kaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehito","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Kiyosawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoi","family":"Komuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Konno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakae","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatada","family":"Mitsuhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Miyakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Muramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Nagasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genji","family":"Nakamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohito","family":"Nonoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Ohira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinobu","family":"Okajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Osawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Oyachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadayo","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuko","family":"Toda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeko","family":"Yagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Yoshimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzuru","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2025.11.036_bib0001","first-page":"309","article-title":"Revised definition and diagnostic criteria for dry eye in Japan (2016 edition)","volume":"34","year":"2017","journal-title":"J Eye"},{"issue":"1","key":"10.1016\/j.ajo.2025.11.036_bib0002","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jtos.2016.09.003","article-title":"New perspectives on dry eye definition and diagnosis: a consensus report by the Asia Dry Eye Society","volume":"15","author":"Tsubota","year":"2017","journal-title":"Ocul Surf"},{"issue":"3","key":"10.1016\/j.ajo.2025.11.036_bib0003","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II definition and classification report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"issue":"3","key":"10.1016\/j.ajo.2025.11.036_bib0004","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II Epidemiology Report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul Surf"},{"issue":"3","key":"10.1016\/j.ajo.2025.11.036_bib0005","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","article-title":"TFOS DEWS II Pathophysiology Report","volume":"15","author":"Bron","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.ajo.2025.11.036_bib0006","first-page":"489","article-title":"Dry eye treatment guidelines","volume":"123","year":"2019","journal-title":"J Jpn Ophthalmol Soc"},{"issue":"4","key":"10.1016\/j.ajo.2025.11.036_bib0007","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.4103\/IJO.IJO_3020_22","article-title":"Ion channels in dry eye disease","volume":"71","author":"Ashok","year":"2023","journal-title":"Indian J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2025.11.036_bib0008","doi-asserted-by":"crossref","first-page":"175","DOI":"10.31083\/j.fbl2905175","article-title":"TRPV1 in dry eye disease","volume":"29","author":"Gou","year":"2024","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"3","key":"10.1016\/j.ajo.2025.11.036_bib0009","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II Management and Therapy Report","volume":"15","author":"Jones","year":"2017","journal-title":"Ocul Surf"},{"issue":"1","key":"10.1016\/j.ajo.2025.11.036_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2020-000697","article-title":"Dry eye: why artificial tears are not always the answer","volume":"6","author":"Kim","year":"2021","journal-title":"BMJ Open Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2025.11.036_bib0011","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3390\/jcm8081120","article-title":"Treatment trends in dry eye disease and factors associated with ophthalmic follow-up discontinuation in Japan","volume":"8","author":"Uchino","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.ajo.2025.11.036_bib0012","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.2147\/OPTH.S226168","article-title":"Real-world treatment patterns of cyclosporine ophthalmic emulsion and lifitegrast ophthalmic solution among patients with dry eye","volume":"13","author":"White","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ajo.2025.11.036_bib0013","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2147\/OPTH.S233194","article-title":"Treatment satisfaction among patients using anti-inflammatory topical medications for dry eye disease","volume":"14","author":"White","year":"2020","journal-title":"Clin Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2025.11.036_bib0014","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.3390\/pharmaceutics14091859","article-title":"Transient receptor potential channels: important players in ocular pain and dry eye disease","volume":"14","author":"Fakih","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.ajo.2025.11.036_bib0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jtos.2017.10.001","article-title":"Neuropathic pain and dry eye","volume":"16","author":"Galor","year":"2018","journal-title":"Ocul Surf"},{"issue":"3","key":"10.1016\/j.ajo.2025.11.036_bib0016","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jtos.2017.05.002","article-title":"TFOS DEWS II Pain and Sensation Report","volume":"15","author":"Belmonte","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.ajo.2025.11.036_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2020.598678","article-title":"Chronic tear deficiency sensitizes transient receptor potential vanilloid 1-mediated responses in corneal sensory nerves","volume":"14","author":"Masuoka","year":"2020","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"10.1016\/j.ajo.2025.11.036_bib0018","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1167\/iovs.10-5801","article-title":"TRPV1 activation is required for hypertonicity-stimulated inflammatory cytokine release in human corneal epithelial cells","volume":"52","author":"Pan","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2025.11.036_bib0019","series-title":"Paper presented at: World Ophthalmology Congress","article-title":"Effects of a Novel TRPV1 Antagonist, SJP-0132, on ocular surface dysfunctions in scopolamine-induced dry eye rat model","author":"Atsumi","year":"2024"},{"key":"10.1016\/j.ajo.2025.11.036_bib0020","series-title":"Results of a randomized, double-masked, placebo-controlled phase 1\/2 study of SJP-0132, a TRPV1 antagonist for dry eye disease [poster presentation]","author":"Wada","year":"2024"},{"issue":"2","key":"10.1016\/j.ajo.2025.11.036_bib0021","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clae.2009.12.010","article-title":"Validation of the 5-item dry eye questionnaire (DEQ-5): discrimination across self-assessed severity and aqueous tear deficient dry eye diagnoses","volume":"33","author":"Chalmers","year":"2010","journal-title":"Cont Lens Anterior Eye"},{"issue":"10","key":"10.1016\/j.ajo.2025.11.036_bib0022","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1001\/jamaophthalmol.2013.4503","article-title":"Development and Validation of the dry eye-related quality-of-life score questionnaire","volume":"131","author":"Sakane","year":"2013","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2025.11.036_bib0023","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ajo.2005.10.006","article-title":"The incidence and risk factors for developing dry eye after myopic LASIK","volume":"141","author":"De Paiva","year":"2006","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2025.11.036_bib0024","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12974-021-02162-7","article-title":"Capsazepine decreases corneal pain syndrome in severe dry eye disease","volume":"18","author":"Fakih","year":"2021","journal-title":"J Neuroinflammation"},{"issue":"14","key":"10.1016\/j.ajo.2025.11.036_bib0025","doi-asserted-by":"crossref","first-page":"6447","DOI":"10.1167\/iovs.16-20303","article-title":"Safety and efficacy clinical trials for SYL1001, a novel short interfering RNA for the treatment of dry eye disease","volume":"57","author":"Benitez-Del-Castillo","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2025.11.036_bib0026","unstructured":"AbbVie. RESTASIS\u00ae (cyclosporine ophthalmic emulsion) 0.05%: US prescribing information. Available at: https:\/\/www.rxabbvie.com\/pdf\/restasis_pi.pdf. Accessed September 8, 2024."},{"key":"10.1016\/j.ajo.2025.11.036_bib0027","unstructured":"Sun Pharmaceutical Industries Inc. CEQUA\u00ae (cyclosporine ophthalmic solution) 0.09%: US prescribing information. Available at: https:\/\/www.cequa.com\/CequaPI.pdf. Accessed September 8, 2024."},{"key":"10.1016\/j.ajo.2025.11.036_bib0028","unstructured":"Novaliq GmbH. VEVYE (cyclosporine ophthalmic solution) 0.1%: US prescribing information. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217469s000lbl.pdf. Accessed September 8, 2024."},{"issue":"4","key":"10.1016\/j.ajo.2025.11.036_bib0029","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.11.036_bib0030","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.2147\/OPTH.S175065","article-title":"A phase II\/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease","volume":"12","author":"Tauber","year":"2018","journal-title":"Clin Ophthalmol"},{"issue":"31","key":"10.1016\/j.ajo.2025.11.036_bib0031","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000016710","article-title":"Efficacy and safety of 0.05% cyclosporine ophthalmic emulsion in treatment of chinese patients with moderate to severe dry eye disease: a 12-week, multicenter, randomized, double-masked, placebo-controlled phase III clinical study","volume":"98","author":"Chen","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"10.1016\/j.ajo.2025.11.036_bib0032","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.ophtha.2019.03.050","article-title":"A phase 3, Randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease","volume":"126","author":"Goldberg","year":"2019","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ajo.2025.11.036_bib0033","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/jamaophthalmol.2023.0709","article-title":"Efficacy and safety of a water-free topical cyclosporine, 0.1%, solution for the treatment of moderate to severe dry eye disease: the ESSENCE-2 randomized clinical trial","volume":"141","author":"Akpek","year":"2023","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2025.11.036_bib0034","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5301\/ejo.5000779","article-title":"Efficacy and safety of 0.1% cyclosporine a cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial","volume":"26","author":"Leonardi","year":"2016","journal-title":"Eur J Ophthalmol"},{"issue":"10","key":"10.1016\/j.ajo.2025.11.036_bib0035","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1097\/ICO.0000000000002633","article-title":"A Water-free 0.1% cyclosporine a solution for treatment of dry eye disease: results of the randomized phase 2b\/3 essence study","volume":"40","author":"Sheppard","year":"2021","journal-title":"Cornea"},{"issue":"6","key":"10.1016\/j.ajo.2025.11.036_bib0036","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ajo.2011.11.003","article-title":"A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye","volume":"153","author":"Semba","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2025.11.036_bib0037","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ophtha.2013.09.015","article-title":"Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study","volume":"121","author":"Sheppard","year":"2014","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.ajo.2025.11.036_bib0038","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.ophtha.2015.08.001","article-title":"Lifitegrast Pphthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized phase III OPUS-2 study","volume":"122","author":"Tauber","year":"2015","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2025.11.036_bib0039","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ophtha.2016.09.025","article-title":"Lifitegrast for the treatment of dry eye disease: results of a phase III, randomized, double-masked, placebo-controlled trial (OPUS-3)","volume":"124","author":"Holland","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.11.036_bib0040","unstructured":"Bausch & Lomb Americas Inc. Xiidra (lifitegrast ophthalmic solution) 5%: US prescribing information. Available at: https:\/\/pi.bausch.com\/globalassets\/pdf\/packageinserts\/pharma\/xiidra-prescribing-information.pdf. Accessed September 8, 2024."},{"issue":"6","key":"10.1016\/j.ajo.2025.11.036_bib0041","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/ICO.0000000000000803","article-title":"Safety of lifitegrast ophthalmic solution 5.0% in patients with dry eye disease: a 1-year, multicenter, randomized, placebo-controlled study","volume":"35","author":"Donnenfeld","year":"2016","journal-title":"Cornea"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425006348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425006348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:15:21Z","timestamp":1781788521000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939425006348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":41,"alternative-id":["S0002939425006348"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2025.11.036","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of SJP-0132 in Patients With Dry Eye Disease: A Phase 2b Randomized, Double-Masked, Dose-Finding Study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2025.11.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}